INmune Bio (INMB)

Executive Summary

INmune Bio is a clinical-stage biotechnology company pioneering a 'scalpel' approach to immunotherapy, developing first-in-class biologics that selectively modulate the innate immune system. The company's lead programs include XPro1595, a dominant-negative inhibitor of soluble TNF, for Alzheimer's disease, and INKmune, a Natural Killer cell priming platform for cancer. Despite multiple terminated or withdrawn trials, INmune has generated key data: a Phase 2 Alzheimer's study (NCT05318976) was completed in May 2025, and a Phase 1/2 INKmune study in metastatic castration-resistant prostate cancer (mCRPC) was completed in September 2025. The company remains focused on advancing these candidates toward pivotal trials, leveraging its unique mechanism to restore immune function without broad immunosuppression.

Upcoming Catalysts (preview)

• 2026Presentation of Phase 2 XPro1595 Alzheimer's data at a major medical conference90% success
• Q3 2026Initiation of a Phase 2/3 trial for INKmune in mCRPC70% success
• 2026Announcement of a strategic partnership or licensing deal for XPro159550% success